NCT02902679View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
ThrombosisFactor XIRenal ImpairmentESRD (End-Stage Renal Disease)
Interventions
DRUG

BMS-986177

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02902679 - A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment | Biotech Hunter | Biotech Hunter